Results 21 to 30 of about 5,159 (106)

Genetic polymorphisms of CYP3A5, CHRM2, and ZNF498 and their association with epilepsy susceptibility: a pharmacogenetic and case–control study

Pharmacogenomics and Personalized Medicine, 2019
Laith N AL-Eitan1,2, Islam M Al-Dalalah1, Mohamed M Mustafa3, Mansour A Alghamdi4, Afrah K Elshammari5, Wael H Khreisat5, Mohammed N Al-Quasmi6, Hanan A Aljamal1 1Department of Applied Biological Sciences, Jordan University of Science and Technology ...
AL-Eitan LN, Al-Dalalah IM, Mustafa MM, Alghamdi MA, Elshammari AK, Khreisat WH, Al-Quasmi MN, Aljamal HA   +7 more
doaj  

In Vitro Assessment of Drug‐Induced Liver Injury Using Three‐Dimensional Cultured HepaSH Cells Derived From Chimeric Mouse Model With Humanized Liver

Journal of Applied Toxicology, Volume 45, Issue 12, Page 2641-2653, December 2025.
ABSTRACT Drug‐induced liver injury (DILI) is a serious adverse event and a common cause of postmarketing drug withdrawal. Despite nonclinical assessments of DILI risk, which are predominantly conducted in experimental animals, DILI remains a frequent adverse event, highlighting the need to improve nonclinical assessments.
Xingming Liu, Yuichiro Higuchi, Yuta Sakamoto, Shota Yanagida, Shotaro Uehara, Hiroshi Suemizu, Yasunari Kanda, Hiroyuki Kawagishi   +7 more
wiley   +1 more source

The Concise Guide to PHARMACOLOGY 2025/26: Enzymes

British Journal of Pharmacology, Volume 182, Issue S1, Page S307-S403, December 2025.
The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander, Doriano Fabbro, Alasdair J. Gibb, Eamonn Kelly, Alistair A. Mathie, Chloe J. Peach, Emma L. Veale, Jane F. Armstrong, Elena Faccenda, Simon D. Harding, Christopher Southan, Jamie A. Davies, Stephanie Annett, Detlev Boison, Kathryn Elisa Burns, Carmen Dessauer, Jürg Gertsch, Nuala Ann Helsby, Angelo A. Izzo, Rennolds Ostrom, Ester Pagano, Andreas Papapetropoulos, Nigel J. Pyne, Susan Pyne, Tracy Robson, Roland Seifert, Johannes‐Peter Stasch, Csaba Szabo, Mario van der Stelt, Albert van der Vliet, Val Watts, Szu Shen Wong   +31 more
wiley   +1 more source

Tuberculous Retroperitoneal Lymphadenitis After Kidney Transplantation That Was Difficult to Diagnose and Treat: A Case Report

IJU Case Reports, Volume 8, Issue 6, Page 558-562, November 2025.
ABSTRACT Introduction We present a rare case of tuberculous retroperitoneal lymphadenitis after kidney transplantation that was difficult to diagnose and treat. Case Presentation A 52‐year‐old man who received a kidney transplantation from his wife presented with right lower quadrant pain.
Ryota Nakayasu, Yuki Kita, Yuki Teramoto, Kenji Nakamura, Toru Sakatani, Kimihiko Masui, Takayuki Goto, Ryoichi Saito, Takashi Kobayashi   +8 more
wiley   +1 more source

Derivation of a health‐based guidance value for Δ8‐tetrahydrocannabinol (Δ8‐THC) and its occurrence in food

EFSA Journal, Volume 23, Issue 11, November 2025.
Abstract The European Food Safety Authority (EFSA) was asked to deliver a scientific opinion on the derivation of a health‐based guidance value (HBGV) for Δ8‐tetrahydrocannabinol (Δ8‐THC) in food with an assessment of the occurrence of Δ8‐THC and the co‐occurrence with Δ9‐THC in hemp and hemp‐derived products.
EFSA Panel on Contaminants in the Food Chain (CONTAM), Helle Katrine Knutsen, Agneta Åkesson, Vasileios Bampidis, Margherita Bignami, James Kevin Chipman, Gisela Degen, Antonio Hernández‐Jerez, Tim Hofer, Christer Hogstrand, Stefano Landi, Jean‐Charles Leblanc, Kyriaki Machera, Evangelia Ntzani, Isabelle P. Oswald, Guido Rychen, Salomon Sand, Katharina Vejdovszky, Barbara Viviani, Birgit Dusemund, Carlo Nebbia, Stefan Weigel, Claudia Cascio, Anna Christodoulidou, José Cortiñas Abrahantes, Bruno Dujardin, Andrea Gissi, Lydia Alarcón Asensio, Eleni Gkimprixi, Tuuli Tauriainen, Laurent Bodin   +30 more
wiley   +1 more source

Population Pharmacokinetic and Exposure‐Response Analyses of Ibrutinib Combined With Bendamustine and Rituximab in Patients With Mantle Cell Lymphoma

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 10, Page 1562-1574, October 2025.
ABSTRACT Efficacy and safety of ibrutinib 560 mg once daily or placebo combined with bendamustine and rituximab (BR) were assessed in patients with mantle cell lymphoma in a randomized phase 3 study (SHINE). The analysis described explores the ibrutinib population pharmacokinetics (PK) and exposure‐response (E‐R) relationships of selected efficacy and ...
Per Olsson Gisleskog, Belén Valenzuela, Nicoline Treijtel, Sanjay Deshpande, Todd Henninger, Juan José Perez‐Ruixo   +5 more
wiley   +1 more source

Association of Metabolic Genotype Composite CYP3A5*3 and CYP3A4*1B to Tacrolimus Pharmacokinetics in Stable Black and White Kidney Transplant Recipients

Clinical and Translational Science, Volume 18, Issue 10, October 2025.
ABSTRACT Interpatient variability in tacrolimus pharmacokinetics is due in part to variation in metabolism by cytochrome P‐450 3A5 and 3A4 and membrane transport by P‐glycoprotein. We evaluated the combined role CYP3A5*3 and CYP3A4*1B genotypes have on tacrolimus pharmacokinetics in 65 stable Black and White kidney transplant recipients receiving ...
Daniel Brazeau, Kristopher Attwood, Louse M. Cooper, Vanessa Gray, Shirley Chang, Shirley Chen, Brian M. Murray, Kathleen M. Tornatore   +7 more
wiley   +1 more source

Effect of Mild to Moderate Hepatic Impairment on Valemetostat Pharmacokinetics: An Open‐Label, Phase I Study

Clinical Pharmacology in Drug Development, Volume 14, Issue 8, Page 631-641, August 2025.
Abstract Valemetostat tosylate (valemetostat) is a dual inhibitor of enhancer of zeste homolog (EZH) 2 and EZH1, approved in Japan for the treatment of relapsed/refractory peripheral T‐cell lymphoma and adult T‐cell leukemia/lymphoma. This Phase I, open‐label study evaluated the pharmacokinetics and safety of a single 50‐mg oral dose of valemetostat in
Masaya Tachibana, Thuy Vu Craveiro, Thomas C. Marbury, Samuel Oberstein, George J. Atiee, Ben Tao, Takako Shimizu, Yvonne Lau, Malaz A. Abutarif   +8 more
wiley   +1 more source

Drug Exposure in Chronic Kidney Disease: It Is Not Just About the Glomerular Filtration Rate

Fundamental &Clinical Pharmacology, Volume 39, Issue 4, Page 1-10, August 2025.
ABSTRACT Chronic kidney disease (CKD) affects over 10% of the world's population and is associated with high morbidity and mortality rates. The management of CKD is complex; CKD alters drug pharmacokinetics and pharmacodynamics and further complicates therapeutic strategies regimens.
Sophie Liabeuf, Jessica Berdougo‐Tritz, Lucie Augey, Aïcha Mbarek, Michel Jadoul, Gilbert Deray, Ziad A. Massy   +6 more
wiley   +1 more source

Expert Consensus on the Clinical Application of PI3K/AKT/mTOR Inhibitors in the Treatment of Breast Cancer (2025 Edition)

Cancer Innovation, Volume 4, Issue 3, June 2025.
ABSTRACT Background The phosphoinositide 3‐kinase (PI3K)/protein kinase B (PKB or AKT)/mammalian target of rapamycin (mTOR) signaling pathway (PAM pathway) plays a critical role in breast cancer pathogenesis and progression, and is closely linked with resistance to endocrine therapy in advanced breast cancer.
The Breast Cancer Expert Committee of the National Quality Control Center for Cancer, The Expert Committee on Cancer Prevention and Treatment of the Health China Research Center, The Society of Clinical Research on Oncology Medications of the China Anti‐Cancer Association, The Society of Onco‐Pathology of the China Anti‐Cancer Association   +3 more
wiley   +1 more source